IP Library › Granted Patent US 8,173,123
Granted Patent B2
US 8,173,123 · App. 12/709,029 · Granted May 8, 2012

Methods of treating colitis involving IL-13 and NK-T cells

Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services; Brigham & Women's Hospital
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,173,123
App. No.
12/709,029
Granted
May 8, 2012
Kind
B2
Abstract

Method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates IL-13 activity (FIG. 3 ). The invention also provides a method of treating or preventing the inflammatory response of colitis in a subject comprising administering to the subject an effective amount of a substance that modulates NK-T cell activity. The invention also provides for the screening of substances that treat or prevent the inflammatory response of colitis.

Claims (4)

1. A method of treating the inflammatory response of ulcerative colitis in a subject comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof that binds to CD1.

2. The method of claim 1 , wherein the subject is a human.

3. The method of claim 1 , wherein the ulcerative colitis is caused by an inflammatory bowel disorder.

4. The method of claim 1 , further comprising administration of an antibody that binds to Vα14 Jα281 or Vα14 Jα18.

Assignments (1)
CONFIRMATORY LICENSE Recorded Mar 20, 2023
From: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 063035/0459 →
Continuity (2)
Division 10517898
Related Publication 20100143339A1 · Jun 10, 2010